Related Experiment Video
Updated: Jun 5, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Response of carbamzepine in bipolar disorder: kindlers versus non-kindlers
Subhash Chandra Das1, Subhash Chandra Gupta, Soumya Basu
1SUBHASH CHANDRA DAS, D.P.M., Senior Resident, Department of Psychiatry, Central Institute of Psychiatry, Kanke, Ranchi-834006.
Abstract:
Based on carbamazepine's hypothesized ability to stabilize temporal lobe seizures and behavioral disorders and its ability to inhibit limbic system excitability in models such as kindling, we undertook this study with the aims of finding out the response of carbamazepine in kindler and non kindler groups and to see the relationship of socio-demographic and clinical variables in kindler and non-kindler bipolar mood disorder with response to carbamazepine. Simple random sampling was done and patients (over a period of one and a half year) between 18-50 years who had a diagnosis of Bipolar Affective Disorder, current episode mania as per lCD-10 and who had history of at least three manic or depressive episode in the past were taken. The total sample was divided into two groups i. e. kindler and non-kindlers. Kindlers were defined as patients with 3 or more affective episodes in less than equal to 1 year apart. Non-kindlers were defined as patients with at least 3 episodes in the past with inter episodic period of more than 1 year. All the patients included in this study were followed up for 6 months and were given carbamazepine in adequate dosages. Fifty -five patients completed the 6 months follow up. Results showed that there was no significant difference between the two groups based on sex, past history of substance intake, type of mood (irritable versus elated), number of relapses during the follow-up and improvement on carbamazepine. Our study does not support the kindling hypothesis.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Bipolar Disorder
Psychosis: Goals of Pharmacotherapy
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Psychosis and Antipsychotic Drugs: Overview